Glycine transporter inhibition reverses ketamine-induced working memory deficits
BM Roberts, CL Shaffer, PA Seymour, CJ Schmidt… - …, 2010 - journals.lww.com
Glycine transporter inhibitors have recently been reported to improve symptoms in patients
with schizophrenia. Here we used acute ketamine in the nonhuman primate to test the
effectiveness of the novel glycine transporter inhibitor, PF-3463275, in a model of cognitive
dysfunction relevant to schizophrenia. PF-3463275 (0.01–0.17 mg/kg; subcutaneously) or a
vehicle was given before the administration of ketamine (median dose of 1.0 mg/kg
intramuscularly) or placebo (saline). Ketamine induced hallucinatory-like behaviors that …
with schizophrenia. Here we used acute ketamine in the nonhuman primate to test the
effectiveness of the novel glycine transporter inhibitor, PF-3463275, in a model of cognitive
dysfunction relevant to schizophrenia. PF-3463275 (0.01–0.17 mg/kg; subcutaneously) or a
vehicle was given before the administration of ketamine (median dose of 1.0 mg/kg
intramuscularly) or placebo (saline). Ketamine induced hallucinatory-like behaviors that …